UCART20x22

BIOLOGICAL2 trials

Sponsors

Cellectis, Cellectis S.A.

Conditions

B-cell Non-Hodgkin Lymphoma (B-NHL)Relapsed or refractory B-cell Non-Hodgkin lymphoma

Phase 1

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

RecruitingNCT05607420

Cellectis S.A.B-cell Non-Hodgkin Lymphoma (B-NHL)

Start: 2022-11-01End: 2027-08-31Target: 80Updated: 2025-08-24

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

RecruitingCTIS2022-501607-27-00

CellectisRelapsed or refractory B-cell Non-Hodgkin lymphoma

Start: 2026-01-06Target: 48Updated: 2026-01-08

Related Papers

Trial in progress: Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) nathali-01

Blood2025-11-03

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Blood2023-11-0214 citations

NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL)

Hematological Oncology2023-06-01